What ChondroFiller actually does — and why it differs from a filler

"Gel" is the word that trips most patients up. Because ChondroFiller arrives as a liquid and sets inside the joint, it is easy to assume it works like a lubricant injection or a permanent joint filler — it does neither.

ChondroFiller is a Class III CE-marked injectable collagen scaffold. Its job is structural: once placed into a focal cartilage defect under ultrasound guidance, the liquid polymerises into a porous, three-dimensional matrix that physically occupies the damaged area. Critically, the scaffold is acellular — it contains no living cells, so no tissue biopsy or cell-harvesting step is required before treatment. Instead, the polymerised matrix functions as a chemotactic structure, drawing the patient's own mesenchymal progenitor cells from the surrounding synovium and subchondral bone marrow into the defect, where they may attach, proliferate, and begin depositing cartilage-like matrix over subsequent months. This process — acellular matrix-induced chondrogenesis — places ChondroFiller in a separate treatment category from viscosupplementation (hyaluronic acid, which supplements joint fluid but does not address the structural defect) and from polyacrylamide hydrogels such as Arthrosamid, which cushion the synovial environment but remain inert and non-regenerative.

How the collagen gel sets inside the joint

The delivery system is a dual-barrel syringe — one chamber holding the ultrapure native type I collagen solution, the other a neutralisation buffer. During the outpatient appointment, as the clinician advances the tip into the defect under ultrasound guidance, the two solutions pass through a mixing adapter and combine for the first time.

That mixing is the trigger. Neutralisation shifts the pH of the acidic collagen solution toward physiological range, initiating polymerisation: the liquid transitions from a viscous injectable into a firm, porous three-dimensional scaffold. The process takes approximately 3 to 5 minutes inside the joint — the collagen conforms precisely to the shape of the defect as it sets, filling uneven surfaces, small tears, and recesses that would be difficult to reach any other way. No bone drilling, marrow stimulation, or fibrin glue is needed to anchor the material; it holds itself in place by taking the shape of the cavity.

The brief setting window carries one practical implication for the hours that follow. Because the hydrogel remains mechanically vulnerable until polymerisation is complete, a 2024 biomechanical study found it could not yet protect opposing cartilage during early cyclic loading. Patients are therefore guided to avoid full weight-bearing immediately after the procedure — a precaution that follows directly from how the material behaves, rather than from post-operative convention. Precise delivery during image-guided placement also matters; the evidence on what happens when a defect is overfilled is covered in the outcomes section below.

MMP-13 and cartilage loss — balance, not blockade

ChondroFiller's relationship with MMP-13 is best understood as additive rather than suppressive: it works by increasing what is built inside the defect, not by reducing what the enzyme destroys.

MMP-13 is the principal enzymatic driver of OA cartilage loss. Its particular ability to cleave type II collagen — the structural protein that gives hyaline cartilage its load-bearing strength — makes it a central focus of osteoarthritis research (Hu et al., 2021, PMC7916132). ChondroFiller contains no active-site inhibitor and makes no claim of direct enzymatic suppression. This is not a limitation to apologise for; it reflects a different therapeutic strategy.

By physically covering the defect and serving as a substrate for recruited progenitor cells, the scaffold shifts the local regenerative balance. As those cells begin depositing type II collagen and glycosaminoglycans within the focal zone, new matrix production may come to outpace ongoing MMP-13-driven breakdown — a repair dynamic that can progress once viable tissue starts occupying the cavity. This is balance, not blockade, and it is the honest description of what the product aims to achieve. The biological rationale is grounded in collagen scaffold science broadly; no ChondroFiller-specific molecular studies have directly measured enzyme kinetics at the repair site.

How the scaffold recruits your own repair cells

Think of the polymerised scaffold as a temporary framework — the structure that makes repair possible, not the repair itself. Based on the established behaviour of collagen scaffolds more broadly, once the porous matrix is in place, it begins drawing the body's own mesenchymal progenitor cells inward from two local sources: the surrounding synovium and the subchondral bone marrow lying just beneath the defect. No cells are harvested from the patient before treatment; the scaffold does the recruiting.

Those cells migrate into the collagen network, attach to its porous walls, and — over the following months — may begin differentiating toward a chondrogenic phenotype. If that differentiation occurs, the cells deposit the structural and biochemical constituents of healthy hyaline-like cartilage. Meanwhile, the collagen scaffold itself is gradually resorbed, fading away as the new matrix it has supported takes its place. The implant is a temporary template, not a permanent fixture in the joint.

The extent of that repair is not uniform. How far cells progress along a chondrogenic path — and whether the resulting tissue more closely resembles hyaline cartilage or a fibrocartilaginous equivalent — varies with patient age, defect depth, and the severity of underlying OA. That variability is why 'may differentiate' is the accurate phrasing throughout: the scaffold creates a biological environment in which chondrogenesis is possible, and published series suggest it often occurs, but the individual outcome is not guaranteed. No ChondroFiller-specific cell-tracking studies have yet confirmed the full differentiation sequence directly in humans.

What the clinical evidence shows so far

Published results across knee, hip, and wrist procedures point consistently in the same direction — though the studies are modest in scale, and a large, adequately powered RCT for the knee does not yet exist.

The most rigorous evidence comes from a 2016 prospective randomised study comparing ChondroFiller with microfracture in focal knee defects. IKDC scores improved significantly from baseline at 3, 6, and 12 months (p<0.05). MRI at 52 weeks confirmed good defect filling and progressive cartilage maturation — a structural finding that is distinct from, and supportive of, the clinical score improvement; the two measures should not be conflated.

A 2021 hip arthroscopy cohort (n=26 patients, 12–60-month follow-up) found 17 of 21 evaluable patients achieved good or excellent outcomes at three, four, and five years. The exceptions are informative: patients with pre-existing severe OA (Tönnis grade 2–3) showed poor results. That threshold matters for expectation-setting — the scaffold appears to need some residual biological capacity to recruit and support new tissue.

A 2024 knee series (n=17) replicated significant gains in both Lysholm and IKDC scores, while a 2025 wrist study (n=25) added objective arthroscopic evidence: treated patients showed significantly better cartilage quality than controls at follow-up (median Outerbridge score 1.5 versus 3, p=0.006).

Across these published series, formally reported device-related adverse events and complaints have been cited at approximately 0.06% — a figure that, alongside the absence of adverse events in the 2016 RCT, suggests an encouraging safety profile. The limitation remains scale: until larger trials report, the evidence base should be read as directionally positive and consistent, not as definitive proof of efficacy.

Suitable candidates and the MSK Doctors pathway

Deciding whether ChondroFiller is appropriate depends primarily on defect characteristics. The scaffold performs best in focal, contained cartilage lesions where the surrounding tissue retains enough biological capacity to support cell recruitment. The 2021 hip cohort is instructive here: patients with Tönnis grade 2–3 OA — meaning widespread, advanced disease — showed poor results, while those with more focal damage fared well. A treating consultant will assess defect size, depth, joint loading patterns, and OA severity before recommending the approach; it is not suited to diffuse or end-stage joint involvement.

For readers at the point of wanting to act on that assessment, MSK Doctors offers ChondroFiller as an ultrasound-guided outpatient injection — no surgery, no hospital admission, and no NHS referral required. The Sleaford (NG34) and Grantham (NG31) clinics are the primary access points for patients across Lincolnshire and the wider non-London catchment; for those based in London, the London Cartilage Clinic provides the same pathway. The clinical team will cover post-procedure guidance — including the short window before the gel fully sets during which joint loading should be gentle — at the appointment itself.

Bookings can be made online without a referral at mskdoctors.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Implantation of ChondroFiller Liquid as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing in focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z